source
- Daraxonrasib Monotherapy Elicits Meaningful Responses in Previously Treated, RAS-Mutated Pancreatic CancerPhase 1/2 data showed an ORR of 35% with daraxonrasib in second-line RAS G12-mutated pancreatic ductal adenocarcinoma.onclive · 2mo ago↗ source
- Sylvester Comprehensive Cancer Center Identifies a Screening Gap to Prevent a Type of Leukemia in the U.S.Researchers at Sylvester identified populations in the US where this cancer may be largely preventable by addressing mother‑to‑child transmission of the virus.onclive · 2mo ago↗ source
- EnGene's shares crash on updated pivotal bladder cancer dataEnGene’s latest Phase 2 results on an experimental treatment for certain bladder cancer patients alarmed investors and raised concerns around the therapy’s future prospects. The Canadian biotech's…